Zerbib, Lola
Ladraa, Sophia
Fraissenon, Antoine
Bayard, Charles
Firpion, Marina
Venot, Quitterie
Protic, Sanela
Hoguin, Clément
Thomas, Amandine
Fraitag, Sylvie
Duong, Jean-Paul
Kaltenbach, Sophie
Balducci, Estelle
Lefevre, Coline
Villarese, Patrick
Asnafi, Vahid
Broissand, Christine
Goudin, Nicolas
Nemazanyy, Ivan http://orcid.org/0000-0001-8080-839X
Autret, Gwennhael
Tavitian, Bertrand http://orcid.org/0000-0002-5349-8194
Legendre, Christophe
Arzouk, Nadia
Minard-Colin, Veronique
Chopinet, Caroline
Dussiot, Michael
Adams, Denise M.
Mirault, Tristan
Guibaud, Laurent
Isenring, Paul
Canaud, Guillaume
Article History
Received: 2 October 2023
Revised: 19 April 2024
Accepted: 12 May 2024
First Online: 17 June 2024
Competing interests
: A patent application (“BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum” #WO2017140828A1) has been filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (CNRS), Université Paris Cité, and Assistance Publique-Hôpitaux De Paris (AP-HP) for the use of BYL719 (alpelisib) in the treatment of <i>PIK3CA</i>-related overgrowth spectrum (PROS/CLOVES syndrome). Dr. Canaud is the inventor. This patent is licensed to Novartis. Dr. Canaud receives or has received consulting fees from Novartis, Vaderis, Alkermes, IPSEN and BridgeBio. The other authors declare no other competing interests.